Biondvax Pharmaceuticals Ltd.

biondvax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. biondvax has successfully completed one phase iia and two phase i/ii clinical trials of the lead product, the multimeric-001 universal flu vaccine. in all three trials, the vaccine was shown to be safe and immunogenic, successfully stimulating both humoral and cellular immune responses. biondvax is currently preparing to conduct its next phase ii trial, scheduled to commence in the fourth quarter of 2011, and expected to be completed by the second quarter of 2012.